Bruno Lafont

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada.

Prestwick Pharmaceuticals, Inc. develops drugs for diseases related to the central nervous system. Its drugs are used in curing diseases such as Huntington's, Parkinson's, restless legs syndrome, schizophrenia, autism, Alzheimer's, and sleep apnea diseases. The company was founded in 2002 and is headquartered in Washington DC.

Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France.

Part of Pfizer Inc., Pfizer SAS (France) is a French company that manufactures biopharmaceuticals. The company is based in Paris, France. The company was founded in 2000. Franck Le Breguero has been the CEO of the company since 2016.

J. Uriach y Cia SA manufactures and markets pharmaceutical products. It offers consumer health products, including over-the-counter drugs, food supplements, personal health and wellbeing products, and nutricosmetic products. The company was founded by Juan Uriach Feliu in 1838 and is headquartered in Barcelona, Spain.

Palau Pharma SA is a holding company engaged in the discovery and development of biophamaceuticals for the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, neuropathic pain, and chronic obstructive pulmonary disease. The company was founded on March 13, 1991 and is headquartered in Palau Solita i Plegamans, Spain.

Sage Healthcare Ltd. provides management consulting services to the healthcare industry. The firm's services include strategic analysis and development; mergers and acquisitions; business development, support, and planning; corporate partnering; licensing and venturing; technology and compound brokerage; valuations and value-enhancement planning; forecasting; risk assessment and due diligence; and commercial and technical assessment. The company was founded in 1995 and is headquartered in Great Shelford, GB.

U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany.

Arrow Therapeutics Ltd. operates as a pharmaceutical company that focuses on research and development of novel antiviral drugs. Its products include novel antibacterial, antiviral, antifungal and preclinical compounds. The company was founded in 1998 and is headquartered in Cambridge, the United Kingdom.

Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland.

Actelion Pharmaceuticals UK Ltd. discovers, develops, and markets drugs. Its products are Tracleer for the treatment of pulmonary arterial hypertension and Zavesca, which is used to treat Type 1 Gaucher disease. The company is headquartered in London, UK.

Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland.

Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI.

Pharma Group Santé SAS develops pharmaceutical dispensation solutions. It offers training and product promotion services. The company was founded by François Cadène in 2000 and is headquartered in Marseille, France.